Cargando…
Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study
BACKGROUND: Multiple sclerosis (MS) currently requires long-term treatment with disease-modifying drugs, administered parenterally up to once daily. The need for regular self-injection can be a barrier to treatment for many patients. Autoinjectors can help patients overcome problems or concerns with...
Autores principales: | Devonshire, Virginia, Arbizu, Txomin, Borre, Björn, Lang, Michael, Lugaresi, Alessandra, Singer, Barry, Verdun di Cantogno, Elisabetta, Cornelisse, Peter |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2877661/ https://www.ncbi.nlm.nih.gov/pubmed/20433746 http://dx.doi.org/10.1186/1471-2377-10-28 |
Ejemplares similares
-
A systematic review of relapse rates during pregnancy and postpartum
in patients with relapsing multiple sclerosis
por: Hellwig, Kerstin, et al.
Publicado: (2021) -
Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study
por: Devonshire, Virginia A., et al.
Publicado: (2016) -
Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15
por: Kappos, Ludwig, et al.
Publicado: (2015) -
Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study
por: Camu, William, et al.
Publicado: (2010) -
Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study
por: Singer, Barry, et al.
Publicado: (2012)